Dog veterinary drug interaction evidence
Published: · Updated:
Verified direct-evidence drug-interaction rules scoped to dog, with source citations and species-specific limits.
What does ZooDDI mean by dog evidence?
This page includes only rules whose species field resolves to dog, whose catalogue status is verified, whose inference type is direct and whose evidence contains a citation.
Which verified direct-evidence rules mention dog?
The catalogue contains 55 qualifying rule records for dog, involving acepromazine, buprenorphine, butorphanol, ciclosporin a, clomipramine, cyclosporine, doxycycline, ivermectin, ketoconazole, metoclopramide, metronidazole, phenobarbital, primidone, propofol, tramadol.
Can evidence for this species be applied to another species?
No. Species-specific evidence must not be silently transferred to another animal. Cross-species signals are described separately and are not direct evidence for this page.
Does no matching interaction rule prove safety?
No. A missing rule means the current published catalogue returned no qualifying match. It does not prove safety, compatibility or an appropriate dose.
What counts as direct evidence here?
Direct evidence here means a cited rule with explicit species scope, verified catalogue status and direct inference type. A product-label warning is not automatically a controlled interaction study. These fields do not establish independent expert review, an effect size, incidence or a patient-specific dose.
Published rule summary
Matching records are grouped by combination, species, recorded conditions, severity, role and displayed source context. Counts describe catalogue records, not independent studies. The context column reproduces recorded official-label wording where available. Severity and role are stored catalogue classifications; review the cited label for clinical interpretation.
| Combination | Species | Recorded conditions | Catalogue severity / role | Source context | Sources |
|---|---|---|---|---|---|
| ciclosporin a + ivermectin | dog | ciclosporin a: route oral | major / risk interaction | Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as macrocyclic lactones (e.g. ivermectin and milbemycin) could decrease the efflux of such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity. | [13] [18] [19] [20] |
| ciclosporin a + ivermectin | dog | ciclosporin a: route oral | major / risk interaction | Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as macrocyclic lactones, e.g. ivermectin and milbemycin, could decrease the efflux of such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity. | [1] |
| ciclosporin a + ketoconazole | dog | ciclosporin a: route oral | moderate / risk interaction | The compound class of azoles (e.g. ketoconazole) is known to increase the blood concentration of ciclosporin in cats and dogs, which is considered to be clinically relevant. | [7] |
| ciclosporin a + ketoconazole | dog | ciclosporin a: route oral | moderate / risk interaction | The compound class of azoles (e.g. ketoconazole) is known to increase the blood concentration of ciclosporin in dogs and cats, which is considered to be clinically relevant. | [1] |
| ciclosporin a + macrocyclic lactones (drug class) | dog | ciclosporin a: route oral | major / risk interaction | Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as macrocyclic lactones (e.g. ivermectin and milbemycin) could decrease the efflux of such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity. | [13] [18] [19] [20] |
| ciclosporin a + macrocyclic lactones (drug class) | dog | ciclosporin a: route oral | major / risk interaction | Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as macrocyclic lactones, e.g. ivermectin and milbemycin, could decrease the efflux of such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity. | [1] |
| metoclopramide + acepromazine | dog | metoclopramide: route oral | moderate / risk interaction | Concurrent use of metoclopramide with neuroleptics derivated from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). | [16] |
| metoclopramide + acepromazine | dog | metoclopramide: route subcutaneous | moderate / risk interaction | Concurrent use of metoclopramide with neuroleptics derivated from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). | [21] |
| metoclopramide + acepromazine | dog | metoclopramide: route subcutaneous | moderate / risk interaction | Concurrent use of metoclopramide with neuroleptics derived from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). | [15] |
| phenobarbital + clomipramine | dog | phenobarbital: route oral | moderate / risk interaction | Concurrent use with other drugs having a central depressive action (like narcotic analgesics, morphinic derivates, phenothiazines, antihistamines, clomipramine and chloramphenicol) can increase the effect of phenobarbital. | [2] [3] [4] [8] [9] [10] [11] [12] |
| phenobarbital + clomipramine | dog | phenobarbital: route oral | moderate / risk interaction | Concurrent use with other drugs having a central depressive action (like narcotic analgesics, morphinic derivatives, phenothiazines, antihistamines, clomipramine and chloramphenicol) can increase the effect of Phenobarbital. | [2] [3] [4] [8] [9] [10] [11] [12] |
| phenobarbital + clomipramine | dog | phenobarbital: route oral | moderate / risk interaction | Concurrent use with other drugs having a central depressive action (like narcotic analgesics, morphinic derivatives, phenothiazines, antihistamines, clomipramine and chloramphenicol) can increase the effect of phenobarbital. | [2] [3] [4] [8] [9] [10] [11] [12] |
| phenobarbital + cyclosporine | dog | phenobarbital: route oral | moderate / risk interaction | The plasmatic concentration of a range of drugs (for example cyclosporine, thyroid hormones and theophylline) is decreased in the case of concurrent administration of Phenobarbital. | [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] |
| phenobarbital + cyclosporine | dog | phenobarbital: route oral | moderate / risk interaction | The plasmatic concentration of a range of drugs (for example cyclosporine, thyroid hormones and theophylline) is decreased in the case of concurrent administration of phenobarbital. | [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] |
| phenobarbital + cyclosporine | dog | phenobarbital: route oral | moderate / risk interaction | The plasmatic concentration of cyclosporine, thyroid hormones and theophylline is decreased in the case of concurrent administration of phenobarbital. | [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] |
| phenobarbital + doxycycline | dog | phenobarbital: route oral | moderate / risk interaction | Phenobarbital may enhance the metabolism of, and therefore decrease the effect of, antiepileptics, chloramphenicol, corticosteroids, doxycycline, beta blockers and metronidazole. | [2] [3] [4] [5] [6] |
| phenobarbital + doxycycline | dog | phenobarbital: route oral | moderate / risk interaction | Phenobarbital may reduce the activity of some drugs (e.g. antiepileptics, chloramphenicol, corticosteroids, doxycycline, beta blockers and metronidazole) by increasing the rate of metabolism through induction of drug-metabolising enzymes in liver microsomes. | [2] [3] [4] [5] [6] |
| phenobarbital + ketoconazole | dog | phenobarbital: route oral | moderate / risk interaction | Cimetidine and ketoconazole are inhibitors of hepatic enzymes: concurrent use with phenobarbital can induce an increase of serum concentration of phenobarbital. | [2] [4] [8] [9] [10] [11] [12] |
| phenobarbital + metronidazole | dog | phenobarbital: route oral | moderate / risk interaction | Phenobarbital may enhance the metabolism of, and therefore decrease the effect of, antiepileptics, chloramphenicol, corticosteroids, doxycycline, beta blockers and metronidazole. | [2] [3] [4] [5] [6] |
| phenobarbital + metronidazole | dog | phenobarbital: route oral | moderate / risk interaction | Phenobarbital may reduce the activity of some drugs (e.g. antiepileptics, chloramphenicol, corticosteroids, doxycycline, beta blockers and metronidazole) by increasing the rate of metabolism through induction of drug-metabolising enzymes in liver microsomes. | [2] [3] [4] [5] [6] |
| phenobarbital + primidone | dog | phenobarbital: route oral | moderate / risk interaction | Use of phenobarbital tablets in conjunction with primidone is not recommended as primidone is predominantly metabolised to phenobarbital. | [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] |
| phenobarbital + primidone | dog | phenobarbital: route oral | moderate / risk interaction | Use of phenobarbital tablets in conjunction with primidone is not recommended as primidone is predominantly metabolized to Phenobarbital. | [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] |
| phenobarbital + primidone | dog | phenobarbital: route oral | moderate / risk interaction | Use of phenobarbital tablets in conjunction with primidone is not recommended as primidone is predominantly metabolized to phenobarbital. | [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] |
| propofol + ketoconazole | dog | propofol: formulation emulsion for injection | moderate / risk interaction | Administration of propofol with other drugs that are metabolised by cytochrome P450 (isoenzyme 2B11 in the dog) such as e.g. chloramphenicol, ketoconazole and loperamide, reduces propofol clearance and prolongs recovery from anaesthesia. | [17] |
| tramadol + buprenorphine | dog | tramadol: route oral | moderate / risk interaction | The combination with mixed agonist/antagonists (e.g. buprenorphine, butorphanol) and tramadol is not advisable, because the analgesic effect of a pure agonist may be theoretically reduced in such circumstances. | [14] |
| tramadol + butorphanol | dog | tramadol: route oral | moderate / risk interaction | The combination with mixed agonist/antagonists (e.g. buprenorphine, butorphanol) and tramadol is not advisable, because the analgesic effect of a pure agonist may be theoretically reduced in such circumstances. | [14] |
Evidence sources
These citations are source records, not a count of independent clinical studies. Repeated product labels or editions may carry the same warning.
- official_label
VMD PID:A008769, Cyclavance 100 mg/ml Oral Solution for Dogs and Cats, version b59ab7b8c5e0b1b5d90f3d50388ab5d4 · Open source
- official_label
VMD PID:A010459, Phenotab Flavoured 25 mg Tablets for Dogs, version f4305ed9fcb52a217f6c418dafdebddb · Open source
- official_label
VMD PID:A009070, Soliphen 60 mg Tablets for Dogs, version d6a77810e423e9259380d336b1e368a5 · Open source
- official_label
VMD PID:A012754, Soliphen 15 mg Tablet for Dogs, version 1beb1a1e650b25a2eef8da5e4c24dd1d · Open source
- official_label
VMD PID:A014295, Epiphen Solution 4% w/v, Oral Drops, version 482968fccf61b23da8d6be95042c9f83 · Open source
- official_label
VMD PID:A004308, Epiphen Solution 4% w/v, Oral Drops, version e7572c6d8fae1656c0b58cce7dc5f94c · Open source
- official_label
VMD PID:A008064, Atopica 100 mg/ml Oral Solution for Cats and Dogs, version e7dbeddf99572d9277954c57896f910c · Open source
- official_label
VMD PID:A008421, Epityl 60 mg Flavoured Tablets for Dogs, version 9f81a7d4f40374b5f303102b06819073 · Open source
- official_label
VMD PID:A012279, Phenotab Flavoured 60 mg Tablets for Dogs, version 1eb41f32e4d47c80cb3142201eb6665b · Open source
- official_label
VMD PID:A011773, Epityl 60 mg Flavoured Tablets for Dogs, version a649ac4daa8b6acfbf4dfbfb21ca9a30 · Open source
- official_label
VMD PID:A008420, Lepitil 60 mg Flavoured Tablets for Dogs Phenobarbital, version 938be7ab1b8a5b0407987b1f87782282 · Open source
- official_label
VMD PID:A012277, Phenotab Flavoured 100 mg Tablets for Dogs, version 81c95db2fc157cdaefe36397e2ce4e8f · Open source
- official_label
VMD PID:A005982, Atopica 10 mg Soft Capsules for Dogs, version 55129b8153861c5b8fb26e8360e24bab · Open source
- official_label
VMD PID:A010309, Tramalgesic 50 mg Tablets for Dogs, version 14814cc08bedd692b053682a60b9de81 · Open source
- official_label
VMD PID:A008831, Metomotyl 5 mg/ml Solution for Injection for Cats and Dogs, version b33134733a18a6a44b42fddbfb805c4f · Open source
- official_label
VMD PID:A007820, Emeprid 1 mg/ml Oral Solution for Dogs and Cats, version cf981f88566c484881bc6313c2dea313 · Open source
- official_label
VMD PID:A010229, Propodine 10 mg/ml Emulsion for Injection / Infusion for Dogs and Cats, version ffde37d1d6f8541101ee4b2346c74af8 · Open source
- official_label
VMD PID:A005984, Atopica 50 mg Soft Capsules for Dogs, version da9c97db84064baf06f2df400eda382a · Open source
- official_label
VMD PID:A005983, Atopica 25 mg Soft Capsules for Dogs, version 25f4ba7d832a7751c27ddbb4ab12df8a · Open source
- official_label
VMD PID:A005985, Atopica 100 mg Soft Capsules for Dogs, version acdb26a3b0b17453cac0ddb44fbf8b95 · Open source
- official_label
VMD PID:A007821, Emeprid 5 mg/ml Solution for Injection for Dogs and Cats, version ef1184581d2907f08852448a2ec86324 · Open source
Verified drug pages for this species
These links point only to published pages with their own verified direct-evidence records.
Content responsibility: ZooDDI. This is a source-linked reference for veterinary review, not a diagnosis, prescription or emergency service.